Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Piazza

Showing results (141-150 of 204) with videos related to

Pageof 21
Sort By:
Histopathology|December 20, 2024
CD23 expression in lymphoplasmacytic lymphoma: Clinical-pathological and biological correlationsMarco Pizzi, Nicolò Danesin, Federico Scarmozzino, et al.
American Journal of Hematology|September 6, 2018
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphomaMaria Chiara Tisi, Rossella Paolini, Francesco Piazza, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 5, 2009
3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosisCarmela Gurrieri, Francesco Piazza, Marianna Gnoato, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 3, 2019
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR TreatmentsAndrea Visentin, Monica Facco, Carmela Gurrieri, et al.
Oncotargets and Therapy|October 16, 2020
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic LeukemiaAndrea Visentin, Federica Frezzato, Filippo Severin, et al.
Discover Oncology|December 1, 2025
Extent of bone marrow infiltration predicts disease progression in asymptomatic Waldenström macroglobulinemiaNicolò Danesin, Giovanni Leone, Mattia D'Antiga, et al.
Haematologica|September 7, 2014
Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cellsCristina Gattazzo, Antonella Teramo, Francesca Passeri, et al.
Blood Cancer Journal|February 15, 2018
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myelomaSara Canovas Nunes, Martina Manzoni, Marco Pizzi, et al.
Journal of Hematology & Oncology|November 29, 2013
Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicityLaura Quotti Tubi, Carmela Gurrieri, Alessandra Brancalion, et al.
Blood|March 22, 2013
Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemiaAntonella Teramo, Cristina Gattazzo, Francesca Passeri, et al.
Pageof 21

Showing results (141-150 of 204) with videos related to

Sort By:
Pageof 21
Histopathology|December 20, 2024
CD23 expression in lymphoplasmacytic lymphoma: Clinical-pathological and biological correlationsMarco Pizzi, Nicolò Danesin, Federico Scarmozzino, et al.
American Journal of Hematology|September 6, 2018
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphomaMaria Chiara Tisi, Rossella Paolini, Francesco Piazza, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 5, 2009
3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosisCarmela Gurrieri, Francesco Piazza, Marianna Gnoato, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 3, 2019
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR TreatmentsAndrea Visentin, Monica Facco, Carmela Gurrieri, et al.
Oncotargets and Therapy|October 16, 2020
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic LeukemiaAndrea Visentin, Federica Frezzato, Filippo Severin, et al.
Discover Oncology|December 1, 2025
Extent of bone marrow infiltration predicts disease progression in asymptomatic Waldenström macroglobulinemiaNicolò Danesin, Giovanni Leone, Mattia D'Antiga, et al.
Haematologica|September 7, 2014
Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cellsCristina Gattazzo, Antonella Teramo, Francesca Passeri, et al.
Blood Cancer Journal|February 15, 2018
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myelomaSara Canovas Nunes, Martina Manzoni, Marco Pizzi, et al.
Journal of Hematology & Oncology|November 29, 2013
Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicityLaura Quotti Tubi, Carmela Gurrieri, Alessandra Brancalion, et al.
Blood|March 22, 2013
Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemiaAntonella Teramo, Cristina Gattazzo, Francesca Passeri, et al.
Pageof 21